15:53 , May 4, 2018 |  BC Week In Review  |  Clinical News

Cinclus' severe erosive GERD candidate well tolerated in Phase I

Cinclus Pharma AG (Basel, Switzerland) said single and multiple ascending doses of oral X842 for five days were well tolerated in an open-label, Swedish Phase I trial in about 39 healthy volunteers. The company is...
20:43 , Apr 27, 2018 |  BioCentury  |  Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

CJ-12420: Phase III started

CJ began a double-blind, Korean Phase III trial to compare 100 mg oral CJ-12420 once daily vs. 40 mg oral esomeprazole once daily for up to 8 weeks in about 280 patients. The trial start...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

RQ-00000004: Phase I started

RaQualia began a Japanese Phase I trial of RQ-00000004. The product is in Phase II testing for GERD in Korea. CJ Group’s CJ CheilJedang Co. affiliate has exclusive rights to develop and commercialize RQ-00000004 in...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Vonoprazan fumarate: Phase III data

A double-blind, Japanese Phase III trial in 409 patients with erosive esophagitis showed that once-daily 20 mg oral TAK-438 met the primary endpoint of non-inferiority to once-daily 30 mg lansoprazole in the proportion of patients...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Vonoprazan fumarate: Phase III data

A double-blind, Japanese Phase III trial in 607 patients with healed erosive esophagitis showed that once-daily 10 and 20 mg oral TAK-438 as maintenance treatment each met the primary endpoint of non-inferiority to once-daily 15...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Vonoprazan fumarate: Phase III data

A double-blind, Japanese Phase III trial in 642 patients with a history of gastric or duodenal ulcers who require long-term NSAID therapy showed that once-daily 10 and 20 mg oral TAK-438 each met the primary...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Vonoprazan fumarate: Phase III data

A double-blind, Japanese Phase III trial in 621 patients with a history of gastric or duodenal ulcers who require long-term low-dose aspirin showed that once-daily 10 and 20 mg oral TAK-438 each met the primary...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

Vonoprazan fumarate: Phase III data

A double-blind, double-dummy, Japanese Phase III trial in 650 H. pylori-positive patients with scarred gastric or duodenal ulcers showed that first-line treatment with twice-daily 20 mg oral TAK-438 plus amoxicillin and clarithromycin for 1 week...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

Pariet rabeprazole: Phase III started

Eisai disclosed in its 1Q13 earnings for the period ending June 30 that it began a Japanese Phase III trial to evaluate Pariet rabeprazole in patients resistant to PPIs. Eisai co-promotes a 20 mg tablet...